Advertisement
U.S. Markets closed

Pharnext S.C.A. (ALPHA.PA)

Paris - Paris Delayed Price. Currency in EUR
0.00020.0000 (0.00%)
At close: 04:10PM CET

Pharnext S.C.A.

14 rue de la REpublique
Suresnes 92150
France

https://pharnext.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

NameTitlePayExercisedYear Born
Mr. Daniel E. Cohen M.D., Ph.D.Director319.3kN/A1953
Mr. Hugo Brugiere M.Sc.CEO & ChairmanN/AN/AN/A
Mr. Ilya Chumakov D-Sc, Ph.D.Co-Founder, Chairman of Scientific Advisory Board and DirectorN/AN/AN/A
Mr. Vincent Serra Ph.D.COO & Chief Scientific OfficerN/AN/A1970
Mr. Raj Thota M.Sc.Chief Manufacturing Officer & Head of CMCN/AN/AN/A
Mr. Gilbert Wagener M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.

Corporate Governance

Pharnext S.C.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.